Company intelligence / Profile preview
Kuria Therapeutics
Little Rock*, Arkansas, United Stateskuriatx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Kuria Therapeutics has demonstrated positive preclinical proof-of-concept data for its lead NRF2 activator in both cornea and other ophthalmic models. The company’s approach leverages the activation of the NRF2 pathway to protect and restore vision by addressing mitochondrial dysfunction and oxidative stress as root causes of blinding eye diseases. No clinical-stage results have been reported as of May 2025.
- Therapeutic areas
- OphthalmologyDermatology
- Modalities
- Small molecules (Nrf2 activators)Chemical drugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed as of May 2025.
Beyond the preview
Go deeper on Kuria Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kuria Therapeutics.